Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Infectious Diseases Research Collaboration, Kampala, Uganda.
Lancet HIV. 2023 Aug;10(8):e518-e527. doi: 10.1016/S2352-3018(23)00118-2.
Social and cognitive developmental events can disrupt care and medication adherence among adolescents and young adults living with HIV in sub-Saharan Africa. We hypothesised that a dynamic multilevel health system intervention helping adolescents and young adults and their providers navigate life-stage related events would increase virological suppression compared with standard care.
We did a cluster randomised, open-label trial of young individuals aged 15-24 years with HIV and receiving care in eligible clinics (operated by the government and with ≥25 young people receiving care) in rural Kenya and Uganda. After clinic randomisation stratified by region, patient population, and previous participation in the SEARCH trial, participants in intervention clinics received life-stage-based assessment at routine visits, flexible clinic access, and rapid viral load feedback. Providers had a secure mobile platform for interprovider consultation. The control clinics followed standard practice. The primary, prespecified endpoint was virological suppression (HIV RNA <400 copies per mL) at 2 years of follow-up among participants who enrolled before Dec 1, 2019, and received care at the study clinics. This trial is registered with ClinicalTrials.gov, NCT03848728, and is closed to recruitment.
28 clinics were enrolled and randomly assigned (14 control, 14 intervention) in January, 2019. Between March 14, 2019, and Nov 26, 2020, we recruited 1988 participants at the clinics, of whom 1549 were included in the analysis (785 at intervention clinics and 764 at control clinics). The median participant age was 21 years (IQR 19-23) and 1248 (80·6%) of 1549 participants were female. The mean proportion of participants with virological suppression at 2 years was 88% (95% CI 85-92) for participants in intervention clinics and 80% (77-84) for participants in control clinics, equivalent to a 10% beneficial effect of the intervention (risk ratio [RR] 1·10, 95% CI 1·03-1·16; p=0·0019). The intervention resulted in increased virological suppression within all subgroups of sex, age, and care status at baseline, with greatest improvement among those re-engaging in care (RR 1·60, 95% CI 1·00-2·55; p=0·025).
Routine and systematic life-stage-based assessment, prompt adherence support with rapid viral load testing, and patient-centred, flexible clinic access could help bring adolescents and young adults living with HIV closer towards a goal of universal virological suppression.
Eunice Kennedy Shriver National Institute of Child Health and Human Development, US National Institutes of Health.
社会和认知发展事件会干扰撒哈拉以南非洲地区青少年和青年艾滋病毒感染者的护理和药物依从性。我们假设,一种帮助青少年和青年及其提供者应对与生活阶段相关事件的动态多层次卫生系统干预措施,与标准护理相比,会增加病毒学抑制率。
我们在肯尼亚和乌干达的农村地区进行了一项多中心、开放性、随机对照试验,招募年龄在 15-24 岁之间、正在接受符合条件的诊所(由政府运营,有≥25 名青年接受治疗)治疗的艾滋病毒感染者。在按地区、患者人群和之前参加 SEARCH 试验分层进行诊所随机分组后,干预诊所的参与者在常规就诊时接受基于生活阶段的评估、灵活的诊所就诊机会和快速病毒载量反馈。提供者有一个安全的移动平台用于提供者间咨询。对照诊所则遵循标准做法。主要的、预先规定的终点是在 2019 年 12 月 1 日之前登记并在研究诊所接受治疗的参与者在 2 年随访时达到病毒学抑制(HIV RNA<400 拷贝/毫升)。该试验在 ClinicalTrials.gov 注册,编号为 NCT03848728,目前已停止招募。
2019 年 1 月,有 28 家诊所入组并随机分配(对照组 14 家,干预组 14 家)。在 2019 年 3 月 14 日至 2020 年 11 月 26 日期间,我们在诊所招募了 1988 名参与者,其中 1549 名被纳入分析(对照组 785 名,干预组 764 名)。参与者的中位年龄为 21 岁(IQR 19-23),1549 名参与者中有 1248 名(80.6%)为女性。在 2 年时,干预组中达到病毒学抑制的参与者比例为 88%(95%CI 85-92),对照组为 80%(77-84),相当于干预的 10%有益效果(风险比[RR]1.10,95%CI 1.03-1.16;p=0.0019)。该干预措施在性别、年龄和基线护理状况的所有亚组中均提高了病毒学抑制率,在重新开始护理的人群中改善最大(RR 1.60,95%CI 1.00-2.55;p=0.025)。
常规、系统的基于生活阶段的评估、快速病毒载量检测的即时依从性支持以及以患者为中心的灵活诊所就诊机会,可能有助于使艾滋病毒感染者青少年和青年更接近实现普遍病毒学抑制的目标。
美国国立卫生研究院国立儿童健康与人类发育研究所,美国国立卫生研究院。